JP2020533404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533404A5 JP2020533404A5 JP2020534821A JP2020534821A JP2020533404A5 JP 2020533404 A5 JP2020533404 A5 JP 2020533404A5 JP 2020534821 A JP2020534821 A JP 2020534821A JP 2020534821 A JP2020534821 A JP 2020534821A JP 2020533404 A5 JP2020533404 A5 JP 2020533404A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- molecule
- molecule according
- protein
- gla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 229940096437 Protein S Drugs 0.000 claims 3
- 108010066124 Protein S Proteins 0.000 claims 3
- 102100028885 Vitamin K-dependent protein S Human genes 0.000 claims 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003096 antiparasitic agent Substances 0.000 claims 2
- 229940125687 antiparasitic agent Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 101100009548 Arabidopsis thaliana DHFS gene Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 102100023804 Coagulation factor VII Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims 1
- 102100037765 Periostin Human genes 0.000 claims 1
- 101710199268 Periostin Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102000017975 Protein C Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 101100216053 Saccharomycopsis fibuligera GLA1 gene Proteins 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229940012413 factor vii Drugs 0.000 claims 1
- 229940012426 factor x Drugs 0.000 claims 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000004987 nonapoptotic effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims 1
- 229960001914 paromomycin Drugs 0.000 claims 1
- 108010025221 plasma protein Z Proteins 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 125000006853 reporter group Chemical group 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229960005053 tinidazole Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- -1 transthretin Proteins 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554533P | 2017-09-05 | 2017-09-05 | |
| US201762554530P | 2017-09-05 | 2017-09-05 | |
| US62/554,533 | 2017-09-05 | ||
| US62/554,530 | 2017-09-05 | ||
| US201762569403P | 2017-10-06 | 2017-10-06 | |
| US201762569411P | 2017-10-06 | 2017-10-06 | |
| US62/569,411 | 2017-10-06 | ||
| US62/569,403 | 2017-10-06 | ||
| US201762584565P | 2017-11-10 | 2017-11-10 | |
| US62/584,565 | 2017-11-10 | ||
| US201762593014P | 2017-11-30 | 2017-11-30 | |
| US62/593,014 | 2017-11-30 | ||
| PCT/US2018/049624 WO2019051002A1 (en) | 2017-09-05 | 2018-09-05 | PROCESS FOR INTRACELLULAR DELIVERY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533404A JP2020533404A (ja) | 2020-11-19 |
| JP2020533404A5 true JP2020533404A5 (enExample) | 2021-10-14 |
Family
ID=63714024
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534820A Active JP7365704B2 (ja) | 2017-09-05 | 2018-09-05 | 幹細胞へのペイロードの送達 |
| JP2020534821A Pending JP2020533404A (ja) | 2017-09-05 | 2018-09-05 | 細胞内送達法 |
| JP2020512854A Pending JP2020533976A (ja) | 2017-09-05 | 2018-09-05 | エキソソームを標的化する方法 |
| JP2024041903A Pending JP2024073589A (ja) | 2017-09-05 | 2024-03-18 | エキソソームを標的化する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534820A Active JP7365704B2 (ja) | 2017-09-05 | 2018-09-05 | 幹細胞へのペイロードの送達 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512854A Pending JP2020533976A (ja) | 2017-09-05 | 2018-09-05 | エキソソームを標的化する方法 |
| JP2024041903A Pending JP2024073589A (ja) | 2017-09-05 | 2024-03-18 | エキソソームを標的化する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11981723B2 (enExample) |
| EP (3) | EP3679127A1 (enExample) |
| JP (4) | JP7365704B2 (enExample) |
| KR (2) | KR20200050961A (enExample) |
| CN (2) | CN111065733A (enExample) |
| AU (2) | AU2018328223A1 (enExample) |
| BR (2) | BR112020004319A2 (enExample) |
| CA (2) | CA3074678A1 (enExample) |
| IL (2) | IL272908A (enExample) |
| MX (2) | MX2020002250A (enExample) |
| PE (2) | PE20201263A1 (enExample) |
| SG (2) | SG11202001535RA (enExample) |
| WO (3) | WO2019050997A1 (enExample) |
| ZA (2) | ZA202000650B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3524618B1 (en) | 2013-03-15 | 2023-03-08 | GLAdiator Biosciences, Inc. | Gla domains as targeting agents |
| EP3664830A4 (en) | 2017-08-07 | 2020-07-01 | The Regents of the University of California | RISK-FREE CELL THERAPEUTIC GENERATION PLATFORM |
| AU2018328223A1 (en) | 2017-09-05 | 2020-03-12 | GLAdiator Biosciences, Inc. | Delivery of payloads to stem cells |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| CN110036976B (zh) * | 2019-05-08 | 2021-12-07 | 华南农业大学 | 一种阻断鸡禽白血病病毒垂直传播的方法及其应用 |
| CN110423777A (zh) * | 2019-07-23 | 2019-11-08 | 河南科技大学 | 无荧光染料标记外泌体及其制备方法 |
| CN110711249B (zh) * | 2019-09-19 | 2020-10-27 | 北京化工大学 | 一种溶酶体膜包覆纳米颗粒的制备方法 |
| AU2020364084A1 (en) * | 2019-10-09 | 2022-04-21 | Mayo Foundation For Medical Education And Research | Canine distemper virus hemagglutinin and fusion polypeptides |
| KR102547446B1 (ko) * | 2019-11-29 | 2023-06-26 | 서울대학교산학협력단 | 무표지 폴리다이아세틸렌 리포좀 기반의 엑소좀의 검출 방법 |
| CN111803646B (zh) * | 2020-06-04 | 2022-07-05 | 苏州大学 | 一种实体肿瘤联合治疗组合物 |
| US20210393536A1 (en) * | 2020-06-23 | 2021-12-23 | Board Of Regents, The University Of Texas System | Methods and compositions related to extracellular vesicles |
| KR102659285B1 (ko) * | 2020-08-11 | 2024-04-22 | 경북대학교 산학협력단 | 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도 |
| CN112516110B (zh) * | 2020-10-13 | 2022-05-13 | 北京化工大学 | 一种细胞膜包覆纳米酶的方法 |
| CN112553152B (zh) * | 2020-10-27 | 2024-09-17 | 重庆市铂而斐细胞生物技术有限公司 | 一种快速提高脂肪间充质干细胞外泌体产量的方法 |
| CN112285195B (zh) * | 2020-10-27 | 2021-08-10 | 江南大学 | 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法 |
| KR102285160B1 (ko) * | 2020-12-24 | 2021-08-03 | 주식회사 타임바이오 | 전구세포에서 유래한 다기능성 엑소좀을 포함하는 피부염 예방 또는 치료용 약학적 조성물 |
| KR102739746B1 (ko) * | 2021-10-25 | 2024-12-10 | 인하대학교 산학협력단 | 바르토넬라 헨셀라이 유래 세포외 소포체를 이용한 바르토넬라 감염증 진단 방법 |
| CN114940967B (zh) * | 2022-05-09 | 2024-05-31 | 中山大学 | 母乳细胞外囊泡及其在制备骨修复材料中的应用 |
| TWI872888B (zh) * | 2022-12-30 | 2025-02-11 | 財團法人工業技術研究院 | 用於穩定血液中游離核酸及/或外泌體核酸的組成物、含其之試劑與套組以及其用途 |
| CN116421738B (zh) * | 2023-02-28 | 2024-03-19 | 中国医科大学附属第一医院 | 捕获抗原的溶瘤病毒及其药物组合与制备和应用 |
| KR20240154736A (ko) * | 2023-04-18 | 2024-10-28 | 가톨릭대학교 산학협력단 | 면역관문 억제제의 표적화된 전달을 위한 세포외소포체의 용도 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| WO1992013878A2 (en) | 1991-02-07 | 1992-08-20 | Board Of Trustees Of The University Of Illinois | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| NZ255256A (en) | 1992-08-27 | 1997-02-24 | Deakin Res Ltd | Synthetic peptide antigen analogues with retro, inverso or retro-inverso modification, their use and antibodies against them |
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| AU6985594A (en) | 1993-06-30 | 1995-01-24 | Bonno Nammen Bouma | Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods |
| US5597457A (en) | 1995-01-23 | 1997-01-28 | The Regents Of The University Of California | System and method for forming synthetic protein crystals to determine the conformational structure by crystallography |
| US5840833A (en) | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
| US5929237A (en) | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| EP0965597A4 (en) | 1996-12-27 | 2003-01-08 | Mochida Pharm Co Ltd | CELL MEMBRANE EFFECTIVE DRUGS |
| US6093573A (en) | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
| AU750414B2 (en) | 1998-07-13 | 2002-07-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| EP1105523A4 (en) | 1998-08-13 | 2002-09-25 | Wyeth Corp | ESCHERICHIA COLI GDP-FUCOSE SYNTHETASE CRYSTALLINE STRUCTURE AND METHODS OF USE THEREOF |
| AU4218799A (en) | 1998-08-25 | 2000-03-14 | Scripps Research Institute, The | Methods and systems for predicting protein function |
| US6801860B1 (en) | 1999-02-15 | 2004-10-05 | Genetics Institute, Llc | Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| JP2002003407A (ja) | 2000-06-20 | 2002-01-09 | Medei Sci Puraningu:Kk | ハイドロキシアパタイトカルシウム指向性薬物輸送担体 |
| WO2003017032A2 (en) | 2001-08-14 | 2003-02-27 | Dana-Farber Cancer Institute, Inc. | Computer-based methods of designing molecules |
| US7807174B2 (en) | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| ATE458057T1 (de) | 2003-06-19 | 2010-03-15 | Bayer Healthcare Llc | Varianten der faktor-vii- oder -viia-gla-domäne |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US7989594B2 (en) | 2003-07-01 | 2011-08-02 | Celltech R & D Limited | Modified antibody fab fragments |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| UA88272C2 (ru) * | 2003-08-15 | 2009-10-12 | Борд Оф Трастиз Оф Зе Юниверсити Оф Иллинойс | Применение полипептидов семейства купредоксина в лечении рака |
| EP1744734A2 (en) | 2004-02-20 | 2007-01-24 | Novo Nordisk A/S | Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| ATE491799T1 (de) | 2004-05-26 | 2011-01-15 | Bayer Schering Pharma Ag | Chimäre adenoviren zur verwendung in der krebsbehandlung |
| US7511016B2 (en) | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| MX2007001294A (es) | 2004-08-17 | 2008-03-04 | Zlb Behring Gmbh | Polipeptidos modificados que dependen de vitamina k. |
| CN101146826A (zh) * | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| KR100987547B1 (ko) * | 2006-06-01 | 2010-10-12 | 가톨릭대학교 산학협력단 | 냉동보관된 제대혈 줄기세포로부터 초기 세포사를 측정하는조성물, 키트 및 그 방법 |
| JP5448840B2 (ja) | 2006-12-22 | 2014-03-19 | プシオクサス・セラピューティクス・リミテッド | 腫瘍退縮アデノウイルスの作出およびその使用 |
| JP5130580B2 (ja) | 2007-01-17 | 2013-01-30 | 独立行政法人放射線医学総合研究所 | 幹細胞における低線量被ばくの検出マーカー、及び該マーカーを用いる幹細胞での低線量被ばくレベルを推定又は検出する方法 |
| BRPI0810172A2 (pt) | 2007-04-13 | 2014-10-14 | Catalyst Biosciences Inc | Polipeptídeos de fator vii modificado e seus usos |
| KR100968839B1 (ko) | 2008-02-25 | 2010-07-09 | 경북대학교 산학협력단 | 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도 |
| TWI465247B (zh) * | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| WO2010006136A2 (en) * | 2008-07-09 | 2010-01-14 | Mayo Foundation For Medical Education And Research | Adenovirus targeting |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US8283167B2 (en) | 2009-02-11 | 2012-10-09 | Clear Vascular Inc. | Preparation of annexin derivatives |
| WO2010151736A1 (en) | 2009-06-25 | 2010-12-29 | The University Of North Carolina At Chapel Hill | Chimeric factor vii molecules |
| US9121007B2 (en) | 2010-01-26 | 2015-09-01 | Anthrogenesis Corporatin | Treatment of bone-related cancers using placental stem cells |
| WO2012087241A1 (en) | 2010-12-20 | 2012-06-28 | Agency For Science, Technology And Research | Method of purifying exosomes |
| WO2012120130A1 (en) | 2011-03-09 | 2012-09-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods to characterize patients suffering from hemolysis |
| ES2682750T5 (en) | 2011-07-18 | 2025-02-04 | Iba Lifesciences Gmbh | Method of reversibly staining a target cell |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| TWI497845B (zh) | 2012-07-18 | 2015-08-21 | Murata Manufacturing Co | Coaxial connector |
| CA2879542A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| KR20140038288A (ko) | 2012-09-19 | 2014-03-28 | 조지타운 유니버시티 | 표적화된 리포솜 |
| EP3524618B1 (en) * | 2013-03-15 | 2023-03-08 | GLAdiator Biosciences, Inc. | Gla domains as targeting agents |
| CN106414503A (zh) * | 2014-03-11 | 2017-02-15 | 分子模板公司 | 包含邻近氨基酸端的志贺毒素a亚基效应子区和细胞靶向性免疫球蛋白型结合区的蛋白 |
| CN113831416A (zh) * | 2014-06-11 | 2021-12-24 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
| CN105457032A (zh) | 2014-08-11 | 2016-04-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 靶向癌干细胞的碳纳米管-盐霉素药物递送系统、其制备方法及用途 |
| WO2017118764A1 (en) * | 2016-01-07 | 2017-07-13 | Thomas Brocker | Novel approaches for the in vivo and in vitro visualization of dying cells |
| CN105567642B (zh) | 2016-02-01 | 2019-07-12 | 中国科学院生物物理研究所 | 一种着色性干皮病人多能干细胞的制备方法 |
| AU2018328223A1 (en) | 2017-09-05 | 2020-03-12 | GLAdiator Biosciences, Inc. | Delivery of payloads to stem cells |
-
2018
- 2018-09-05 AU AU2018328223A patent/AU2018328223A1/en not_active Abandoned
- 2018-09-05 US US16/643,997 patent/US11981723B2/en active Active
- 2018-09-05 JP JP2020534820A patent/JP7365704B2/ja active Active
- 2018-09-05 MX MX2020002250A patent/MX2020002250A/es unknown
- 2018-09-05 MX MX2020002442A patent/MX2020002442A/es unknown
- 2018-09-05 WO PCT/US2018/049618 patent/WO2019050997A1/en not_active Ceased
- 2018-09-05 AU AU2018330427A patent/AU2018330427A1/en not_active Abandoned
- 2018-09-05 KR KR1020207005896A patent/KR20200050961A/ko not_active Ceased
- 2018-09-05 WO PCT/US2018/049619 patent/WO2019050998A1/en not_active Ceased
- 2018-09-05 JP JP2020534821A patent/JP2020533404A/ja active Pending
- 2018-09-05 SG SG11202001535RA patent/SG11202001535RA/en unknown
- 2018-09-05 JP JP2020512854A patent/JP2020533976A/ja active Pending
- 2018-09-05 US US16/643,964 patent/US20200407422A1/en not_active Abandoned
- 2018-09-05 BR BR112020004319-2A patent/BR112020004319A2/pt not_active IP Right Cessation
- 2018-09-05 US US16/643,942 patent/US20200407421A1/en not_active Abandoned
- 2018-09-05 EP EP18779854.1A patent/EP3679127A1/en active Pending
- 2018-09-05 CA CA3074678A patent/CA3074678A1/en active Pending
- 2018-09-05 EP EP18789264.1A patent/EP3679129A1/en not_active Withdrawn
- 2018-09-05 PE PE2020000281A patent/PE20201263A1/es unknown
- 2018-09-05 CN CN201880057602.7A patent/CN111065733A/zh active Pending
- 2018-09-05 KR KR1020207007278A patent/KR20200050975A/ko active Pending
- 2018-09-05 WO PCT/US2018/049624 patent/WO2019051002A1/en not_active Ceased
- 2018-09-05 CA CA3074291A patent/CA3074291A1/en active Pending
- 2018-09-05 PE PE2020000305A patent/PE20201462A1/es unknown
- 2018-09-05 SG SG11202001536PA patent/SG11202001536PA/en unknown
- 2018-09-05 EP EP18779855.8A patent/EP3679128A1/en not_active Withdrawn
- 2018-09-05 CN CN201880056194.3A patent/CN111051500A/zh active Pending
- 2018-09-05 BR BR112020003945-4A patent/BR112020003945A2/pt not_active IP Right Cessation
-
2020
- 2020-01-30 ZA ZA2020/00650A patent/ZA202000650B/en unknown
- 2020-02-18 ZA ZA2020/01012A patent/ZA202001012B/en unknown
- 2020-02-26 IL IL272908A patent/IL272908A/en unknown
- 2020-02-27 IL IL272942A patent/IL272942A/en unknown
-
2024
- 2024-03-18 JP JP2024041903A patent/JP2024073589A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533404A5 (enExample) | ||
| Knežević et al. | Magnetic nanoarchitectures for cancer sensing, imaging and therapy | |
| Ruan et al. | Fluorescent magnetic nanoparticle-labeled mesenchymal stem cells for targeted imaging and hyperthermia therapy of in vivo gastric cancer | |
| Ha et al. | Electro-responsive hydrogel-based microfluidic actuator platform for photothermal therapy | |
| Mu et al. | Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells | |
| Hu et al. | IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma | |
| Ko et al. | A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins | |
| Bartmann et al. | Evaluation of riboflavin transporters as targets for drug delivery and theranostics | |
| Sweeney et al. | Peptide-mediated targeting mesoporous silica nanoparticles: a novel tool for fighting bladder cancer | |
| Zhu et al. | Aptamer-PEG-modified Fe3O4@ Mn as a novel T1-and T2-dual-model MRI contrast agent targeting hypoxia-induced cancer stem cells | |
| Santo et al. | Contributions and future perspectives on the use of magnetic nanoparticles as diagnostic and therapeutic tools in the field of regenerative medicine | |
| JP2015526075A5 (enExample) | ||
| Feng et al. | Identification of an integrin α6‐targeted peptide for nasopharyngeal carcinoma‐specific nanotherapeutics | |
| Ge et al. | Synthesis and characterization of CD133 targeted aptamer–drug conjugates for precision therapy of anaplastic thyroid cancer | |
| Eguchi et al. | Regulatory roles of HSP90-rich extracellular vesicles | |
| Gao et al. | Magnetic nanoparticles for biomedical applications: From diagnosis to treatment to regeneration | |
| CN104784703A (zh) | 一种基于适配体靶向递送microRNA的纳米载体及其制备方法与应用 | |
| Yang et al. | A zwitterionic near-infrared dye linked TrkC targeting agent for imaging metastatic breast cancer | |
| CN105087596A (zh) | 一种cd20核酸适配体及其应用 | |
| Li et al. | Synthesis and antitumor application of antiangiogenetic gold nanoclusters | |
| Qiu et al. | Strategies for targeting peptide-modified exosomes and their applications in the lungs | |
| Das et al. | “Clickable”, trifunctional magnetite nanoparticles and their chemoselective biofunctionalization | |
| Mathiesen et al. | Adipose tissue-derived extracellular vesicles contribute to phenotypic plasticity of prostate cancer cells | |
| Sengupta et al. | Development of a smart scaffold for sequential cancer chemotherapy and tissue engineering | |
| Lee et al. | Dual-functional cyclic peptide switch on mesoporous nanocontainers for selective CD44 targeting and on–off gatekeeping triggered by conformational transformation |